REPLICor updates clinical results demonstrating the achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 9AC’.
REPLICor更新临床结果表明短期暴露在组合与REP 9AC'免疫治疗慢性乙型肝炎患者实现治疗性疫苗的反应。
10 November 2012, Boston, U.S.A. and Nanjing, China.
2012年11月10日，波士顿，美国，南京，中国。
Montreal, Quebec – Friday , November 9th, 2012 – REPLICor is currently undertaking a proof of concept trial in patients with chronic hepatitis B (HBV) undergoing treatment with its nucleic acid polymer (NAP) REP 9AC’ in combination with Zadaxin™ or Pegasys™. The hepatitis B surface antigen protein (HBsAg) is produced in large excess by the HBV infection as subviral particles (SVPs) which act to block the immune response to HBV infection. NAPs act to block the release of SVPs from infected hepatocytes, providing an effective method for clearing HBsAg from the blood. The elimination of HBsAg in the blood of HBV-infected patients is well known to be the best indicator of a curative response to treatment.
蒙特利尔，魁北克 - 周五2012年11月9日 - REPLICor目前正在开展一个概念证明试验的患者与慢性乙肝病毒（HBV）进行组合与日达仙™或派罗欣治疗与核酸聚合物（NAP）REP 9AC在™ 。 B型肝炎表面抗原蛋白（HBsAg）的大量过量产生作用阻止HBV感染的免疫反应的亚病毒颗粒（SVP的）由HBV感染。国家行动方案采取行动，阻止释放SVP的从被感染的肝细胞，从血液中清除乙肝表面抗原提供了一种有效的方法。消除乙肝表面抗原在血液中的HBV感染者的治疗对治疗的反应是最好的指标是众所周知的。
蒙特利尔，魁北克 - 周五2012年11月9日 - REPLICor目前正在开展一个概念证明试验的患者与慢性乙肝病毒（HBV）进行组合与日达仙™或派罗欣治疗与核酸聚合物（NAP）REP 9AC在™ 。 B型肝炎表面抗原蛋白（HBsAg）的大量过量产生作用阻止HBV感染的免疫反应的亚病毒颗粒（SVP的）由HBV感染。国家行动方案采取行动，阻止释放SVP的从被感染的肝细胞，从血液中清除乙肝表面抗原提供了一种有效的方法。消除乙肝表面抗原在血液中的HBV感染者的治疗对治疗的反应是最好的指标是众所周知的。
Updated interim results from REPLICor’s proof of concept trial will be disclosed simultaneously on Saturday Nov 10, 2012 at the 63rd annual meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, U.S.A. and at the 10th annual meeting on International Drug Discovery Science and Technology in Nanjing, China.
更新临时结果REPLICor的证明概念试验将被披露，同时上周六年11月10，2012年在第63届会议的美国协会肝病研究学会（AASLD），美国波士顿和的第十届年度会议上国际药物在中国南京，探索科学与技术。
Patients who had cleared HBsAg from their blood with REP 9AC’ monotherapy were subjected to combination treatment with REP 9AC’ and either Pegasys™ or Zadaxin™. Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. All patients have achieved HBV antibody levels seen in healthy patients after vaccination with a total of 12 weeks of combination treatment and many patients have achieved antibody titers > 1000 mIU / ml. In 8 out of 9 patients who have achieved this therapeutic vaccine-like response, they continue to control their viral infection off treatment. REPLICor expects that short term Zadaxin™ or Pegasys™ treatment given in combination with the HBsAg release inhibitor REP 9AC’ will achieve an effective, therapeutic vaccination in patients with chronic HBV infection, resulting in the achievement of durable immunological control in most patients, regardless of viral genotype or state of their HBV infection.
HBsAg清除从他们的血液与REP 9AC的单药治疗的患者进行联合治疗REP 9AC“，要么派罗欣™或日达仙™。 6-10周的联合治疗，所有患者增加抗乙肝病毒的抗体或免疫功能低下，观察深刻。所有的患者都取得了HBV疫苗接种后抗体水平患者的健康，共12周的联合治疗，许多患者都取得了抗体效价> 1000 mIU / mL的。 8，9例已经实现了这个治疗性疫苗的反应，他们继续控制治疗病毒感染的折扣。 REPLICor预计，短期日达仙™或派罗欣治疗乙肝表面抗原缓释剂REP 9AC结合，实现有效的慢性HBV感染患者，治疗性疫苗，从而在实现持久的免疫控制，大多数患者，无论其HBV感染的病毒基因型或状态。
For the 63rd annual meeting of the American Association for the Study of Liver Disease:
第63届会议的美国协会肝病研究：
以上的问题，希望能在南京会议中得到较详细的答复。
今天才有空登论坛，10号已经过去了，要不然就去南京看去了